Hunan L. Julhakyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hunan L. Julhakyan has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Andrey Borisovich Sudarikov
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
11 shared publications - Alla Mikhailovna Kovrigina
National Medical Research Center for Hematology
6 shared publications - Sergey Mikchailovich Kulikov
National Medical Research Center for Hematology, 125167 Moscow, Russia
6 shared publications - Yulia Alexandrovna Chabaeva
National Medical Research Center for Hematology, 125167 Moscow, Russia
6 shared publications - Bella V. Biderman
National Research Center for Hematology, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167
5 shared publications - Natalya Risinskaya
National Medical Research Center for Hematology, 125167 Moscow, Russia
5 shared publications
Latest Publications
- Open Access
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 278-288
Accessibility of therapy with T-lymphocytes with chimeric antigen receptor anti-CD19 in adult patients with B-cell leukemia and lymphomas
Introduction . Currently, therapy for hematological malignancies using chimeric antigen receptor T-cells (CAR T) has been included in Russian clinical recommendations. Aim : to highlight the medical and organizational aspects of the use and prospects for the development of therapy for hematological malignancies using CAR T-cell products in Russia. Main findings. Currently, CAR-T-cell therapy has been included in Russian clinical recommendations, and regulatory documents have been developed governing the manufacture and use of CAR T-cell products for patients with refractory and relapsed forms of CD19-positive malignant diseases of the blood system. To use a CAR T-cell product, it is necessary to obtain high-quality starting material via leukapheresis for further production. In Russia, centers for apheresis of hematopoietic stem cells exist only in those medical organizations where hematopoietic stem cell transplantation (HSCT) is performed. There are 36 such centers of federal and regional level in Russia for auto-HSCT and 19 for allo-HSCT. The number of patients in Russia who may be recommended anti-CD19 CAR T-cell therapy is about 2,500 people per year. However, given that not all patients for whom this therapy is indicated can undergo it, the actual number of cases of anti-CD19 CAR T-cell product use at present may be 250–300 (maximum 400) cases per year. In Russia, the use of CAR T-cell products occurs both in the form of a high-tech medicinal product and in the form of a biomedical cell product (BMCP). As of May 2026, there are already 3 centers in Russia that have received permission to manufacture and use an anti-CD19 CAR T-cell product in the format of an individual BMCP.
- 7 November 2026
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 71 (3) , 278-288
Open AccessAccessibility of therapy with T-lymphocytes with chimeric antigen receptor anti-CD19 in adult patients with B-cell leukemia and lymphomas
Introduction . Currently, therapy for hematological malignancies using chimeric antigen receptor T-cells (CAR T) has been included in Russian clinical recommendations. Aim : to highlight the medical and organizational aspects of the use and prospects for the development of therapy for hematological malignancies using CAR T-cell products in Russia. Main findings. Currently, CAR-T-cell therapy has been included in Russian clinical recommendations, and regulatory documents have been developed governing the manufacture and use of CAR T-cell products for patients with refractory and relapsed forms of CD19-positive malignant diseases of the blood system. To use a CAR T-cell product, it is necessary to obtain high-quality starting material via leukapheresis for further production. In Russia, centers for apheresis of hematopoietic stem cells exist only in those medical organizations where hematopoietic stem cell transplantation (HSCT) is performed. There are 36 such centers of federal and regional level in Russia for auto-HSCT and 19 for allo-HSCT. The number of patients in Russia who may be recommended anti-CD19 CAR T-cell therapy is about 2,500 people per year. However, given that not all patients for whom this therapy is indicated can undergo it, the actual number of cases of anti-CD19 CAR T-cell product use at present may be 250–300 (maximum 400) cases per year. In Russia, the use of CAR T-cell products occurs both in the form of a high-tech medicinal product and in the form of a biomedical cell product (BMCP). As of May 2026, there are already 3 centers in Russia that have received permission to manufacture and use an anti-CD19 CAR T-cell product in the format of an individual BMCP.
- 26 June 2026
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 48 (2) , 139-149
Systematic solutions for the treatment of AL amyloidosis: standardization of recording, improvement of diagnosis, patient pathways and medical education as the basis for care quality
Objective. To characterize care to patients with AL amyloidosis in accordance with current regulations, to analyze survey data from medical specialists on modern care and to identify current issues in medical education regarding diagnosis and treatment of patients with paraproteinemic hemoblastosis. Material and methods. We analyzed regulatory documents and problematic issues in organization of care for patients with AL amyloidosis taking into account expert assessments from chief hematologists in constituent entities of the Russian Federation. Specialists in care for patients with AL amyloidosis were surveyed. Results. Regulatory acts governing care to patients with AL amyloidosis and status of hematologists as primary specialists for pathogenetic therapy were identified. Patient pathways issues were identified, and potential solutions were proposed (creation of regional regulatory documents regulating patient pathways to receive high-quality care). Survey of specialists identified the need for advanced professional program on organization of care, diagnosis and treatment of patients with AL amyloidosis. Conclusion. Improved treatment of patients with AL amyloidosis is possible in case of state funding for expensive diagnosis and therapy. Correct coding of AL amyloidosis cases will enable organization of a patient registry and outcome monitoring, reduce the period between diagnosis and treatment, as well as facilitate patient pathways. It is necessary to develop and implement advanced educational programs for diagnosis and treatment of AL amyloidosis with practice-oriented training for hematologists, pathologists, and specialists in laboratory testing. Multidisciplinary teams, including hematologist, nephrologist and cardiologist, should be formed to ensure timely diagnosis and treatment, including pathogenetic antitumor targeted therapy.
- 26 June 2026
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 48 (2) , 139-149
Systematic solutions for the treatment of AL amyloidosis: standardization of recording, improvement of diagnosis, patient pathways and medical education as the basis for care quality
Objective. To characterize care to patients with AL amyloidosis in accordance with current regulations, to analyze survey data from medical specialists on modern care and to identify current issues in medical education regarding diagnosis and treatment of patients with paraproteinemic hemoblastosis. Material and methods. We analyzed regulatory documents and problematic issues in organization of care for patients with AL amyloidosis taking into account expert assessments from chief hematologists in constituent entities of the Russian Federation. Specialists in care for patients with AL amyloidosis were surveyed. Results. Regulatory acts governing care to patients with AL amyloidosis and status of hematologists as primary specialists for pathogenetic therapy were identified. Patient pathways issues were identified, and potential solutions were proposed (creation of regional regulatory documents regulating patient pathways to receive high-quality care). Survey of specialists identified the need for advanced professional program on organization of care, diagnosis and treatment of patients with AL amyloidosis. Conclusion. Improved treatment of patients with AL amyloidosis is possible in case of state funding for expensive diagnosis and therapy. Correct coding of AL amyloidosis cases will enable organization of a patient registry and outcome monitoring, reduce the period between diagnosis and treatment, as well as facilitate patient pathways. It is necessary to develop and implement advanced educational programs for diagnosis and treatment of AL amyloidosis with practice-oriented training for hematologists, pathologists, and specialists in laboratory testing. Multidisciplinary teams, including hematologist, nephrologist and cardiologist, should be formed to ensure timely diagnosis and treatment, including pathogenetic antitumor targeted therapy.
- Open Access
- 25 June 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (2) , 125-132
Models of organization and methods of payment for medical care for patients with malignant neoplasms and anemia at the expense of compulsory medical insurance
The availability of medication is directly determined by the ability to reimburse its costs, which determines the appropriateness of anemia therapy and the prognosis for cancer patients. Aim of the work was to assess the potential for financing medical care for patients with malignant neoplasms and anemia using compulsory medical insurance. A review of payment methods for medical care for patients with malignant neoplasms and anemia using compulsory medical insurance funds in accordance with Russian legislation was conducted. Models of medical care organization are identified depending on the suspected etiology of anemia. Suitable payment methods for each model are substantiated. For patients who develop anemia after starting anticancer therapy, there are several options for paying for medical care using compulsory medical insurance: 1) a single clinical statistical group with antitumor therapy [ds19.157–ds19.180; st19.182–st19.202], as well as a patient treatment complexity coefficient sl005 for a concomitant disease – unspecified anemia (International Classification of Diseases, 10th revision code D64.9) (i.e. without an established etiology); 2) 1st clinical statistical group (1st insurance event) with antitumor therapy [ds19.157–ds19.180; st19.182–st19.202]; 2nd clinical statistical group (2nd insurance event) with treatment for anemia of specified etiology (except International Classification of Diseases, 10th revision code D64.9) [ds05.001–ds05.002; st05.001–st05.002]. A decision-making algorithm has been developed to ensure a legal mechanism for the use of treatment complexity coefficient, within the framework of which erythropoiesis-stimulating drugs for unspecified anemia are prescribed before the diagnosis of anemia in malignant neoplasm is established. Compliance with the proposed decision-making algorithm before submitting an insurance claim for payment with treatment complexity coefficient s1005 for unspecified anemia opens up opportunities for insurance coverage of erythropoiesis-stimulating drugs in oncology medical organizations, which increases the availability of drug treatment for patients insured under compulsory medical insurance.
- 25 June 2026
- Published by Publishing House ABV Press in Oncohematology
- Vol. 21 (2) , 125-132
Open AccessModels of organization and methods of payment for medical care for patients with malignant neoplasms and anemia at the expense of compulsory medical insurance
The availability of medication is directly determined by the ability to reimburse its costs, which determines the appropriateness of anemia therapy and the prognosis for cancer patients. Aim of the work was to assess the potential for financing medical care for patients with malignant neoplasms and anemia using compulsory medical insurance. A review of payment methods for medical care for patients with malignant neoplasms and anemia using compulsory medical insurance funds in accordance with Russian legislation was conducted. Models of medical care organization are identified depending on the suspected etiology of anemia. Suitable payment methods for each model are substantiated. For patients who develop anemia after starting anticancer therapy, there are several options for paying for medical care using compulsory medical insurance: 1) a single clinical statistical group with antitumor therapy [ds19.157–ds19.180; st19.182–st19.202], as well as a patient treatment complexity coefficient sl005 for a concomitant disease – unspecified anemia (International Classification of Diseases, 10th revision code D64.9) (i.e. without an established etiology); 2) 1st clinical statistical group (1st insurance event) with antitumor therapy [ds19.157–ds19.180; st19.182–st19.202]; 2nd clinical statistical group (2nd insurance event) with treatment for anemia of specified etiology (except International Classification of Diseases, 10th revision code D64.9) [ds05.001–ds05.002; st05.001–st05.002]. A decision-making algorithm has been developed to ensure a legal mechanism for the use of treatment complexity coefficient, within the framework of which erythropoiesis-stimulating drugs for unspecified anemia are prescribed before the diagnosis of anemia in malignant neoplasm is established. Compliance with the proposed decision-making algorithm before submitting an insurance claim for payment with treatment complexity coefficient s1005 for unspecified anemia opens up opportunities for insurance coverage of erythropoiesis-stimulating drugs in oncology medical organizations, which increases the availability of drug treatment for patients insured under compulsory medical insurance.
- Open Access
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 65-74
Assessment of the need for financial provision of pharmacotherapy for anemia in patients with malignant neoplasms through funds from compulsory medical insurance
Aim: To evaluate the economic feasibility of reimbursing healthcare organizations for the costs of pharmacotherapy for anemia associated with malignant neoplasms during the period of antitumor pharmacotherapy and to propose mechanisms for its financial provision through funds from compulsory medical insurance. Materials and methods: А retrospective economic evaluation was conducted in 13 federal subjects of the Russian Federation, assessing various treatment options for anemia associated with malignant neoplasms in terms of financial expenditures for subsequent medical care delivery. This evaluation determined the effectiveness of anemia treatment based on prevented complications (predictable consequences of progression, including hypoxia, ischemia of organs and tissues, and reduced efficiency of pharmacotherapy), which require insurance coverage through funds from compulsory medical insurance. Results: The estimated costs for procuring erythropoiesis-stimulating agents range from 597.4 million rubles per year to 668.2 million rubles per year. Due to the savings achieved by eliminating the need for insurance coverage to compensate for the costs of treating anemia associated with malignant neoplasms following anticancer drug therapy (prevented insurance cases), a return on investment of 35.0 % is projected within the first 12 months, and 101.7 % within 36 months. Conclusions: The introduction of a separate payment method for medical care, which would enable reimbursement of costs for treating anemia associated with malignant neoplasms concurrently with antitumor pharmacotherapy for each administration of erythropoiesis-stimulating agents, is justified by a prognostic calculation indicating full cost recovery for the procurement of such agents over a 3-year observation period.
- 3 February 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (4) , 65-74
Open AccessAssessment of the need for financial provision of pharmacotherapy for anemia in patients with malignant neoplasms through funds from compulsory medical insurance
Aim: To evaluate the economic feasibility of reimbursing healthcare organizations for the costs of pharmacotherapy for anemia associated with malignant neoplasms during the period of antitumor pharmacotherapy and to propose mechanisms for its financial provision through funds from compulsory medical insurance. Materials and methods: А retrospective economic evaluation was conducted in 13 federal subjects of the Russian Federation, assessing various treatment options for anemia associated with malignant neoplasms in terms of financial expenditures for subsequent medical care delivery. This evaluation determined the effectiveness of anemia treatment based on prevented complications (predictable consequences of progression, including hypoxia, ischemia of organs and tissues, and reduced efficiency of pharmacotherapy), which require insurance coverage through funds from compulsory medical insurance. Results: The estimated costs for procuring erythropoiesis-stimulating agents range from 597.4 million rubles per year to 668.2 million rubles per year. Due to the savings achieved by eliminating the need for insurance coverage to compensate for the costs of treating anemia associated with malignant neoplasms following anticancer drug therapy (prevented insurance cases), a return on investment of 35.0 % is projected within the first 12 months, and 101.7 % within 36 months. Conclusions: The introduction of a separate payment method for medical care, which would enable reimbursement of costs for treating anemia associated with malignant neoplasms concurrently with antitumor pharmacotherapy for each administration of erythropoiesis-stimulating agents, is justified by a prognostic calculation indicating full cost recovery for the procurement of such agents over a 3-year observation period.
- Open Access
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 83-96
Predicting outcomes in patients with anemia and malignant neoplasms
Introduction. Anemia is a common complication of malignancies and anticancer treatment. In this regard, it is of great importance to predict the most likely outcomes in cancer patients with this pathology in the distant and medium periods.Aim. To analyze the factors that determine the prognosis in patients with anemia in malignant neoplasms and develop a methodological approach to predicting adverse, including fatal, outcomes in such patients in 3- and 5-year follow-up periods.Materials and methods. A cohort retrospective study was conducted. A group of patients with anemia in malignant neoplasms who received medical care was identified. To assess the factors that determine the outcome of this pathology, patients are divided according to the binary principle. The minimum sample size was determined using Altman nomograms. methods of non-parametric statistics (χ2-criterium) were used for statistical processing of data. The assessment of factors that cause an unfavorable prognosis in patients with anemia in malignant neoplasms was carried out by calculating the diagnostic coefficient according to A. wald and the informative coefficient according to S. kulbak.Results. It was found that the greatest role in formation of an unfavorable outcome of cancer is played by cardiovascular diseases, diabetes mellitus and cirrhosis of the liver. Among the therapeutic measures, the pathogenetic treatment of anemia with drugs that stimulate erythropoiesis, started during the period of antitumor therapy, has the greatest effect on the favorable outcome, which causes an increase in frequency of favorable outcomes to 5.5 and 4.8 % over 3 and 5 years, respectively.Conclusion. The methodological approach developed by us to assess probabilities of formation of adverse outcomes in patients with anemia in malignant neoplasms can be used to solve expert and clinical problems, determination the risk of an unfavorable outcome and justification the indications for the timely start of therapy.
- 3 November 2025
- Published by Publishing House ABV Press in Head and Neck Tumors (HNT)
- Vol. 15 (3) , 83-96
Open AccessPredicting outcomes in patients with anemia and malignant neoplasms
Introduction. Anemia is a common complication of malignancies and anticancer treatment. In this regard, it is of great importance to predict the most likely outcomes in cancer patients with this pathology in the distant and medium periods.Aim. To analyze the factors that determine the prognosis in patients with anemia in malignant neoplasms and develop a methodological approach to predicting adverse, including fatal, outcomes in such patients in 3- and 5-year follow-up periods.Materials and methods. A cohort retrospective study was conducted. A group of patients with anemia in malignant neoplasms who received medical care was identified. To assess the factors that determine the outcome of this pathology, patients are divided according to the binary principle. The minimum sample size was determined using Altman nomograms. methods of non-parametric statistics (χ2-criterium) were used for statistical processing of data. The assessment of factors that cause an unfavorable prognosis in patients with anemia in malignant neoplasms was carried out by calculating the diagnostic coefficient according to A. wald and the informative coefficient according to S. kulbak.Results. It was found that the greatest role in formation of an unfavorable outcome of cancer is played by cardiovascular diseases, diabetes mellitus and cirrhosis of the liver. Among the therapeutic measures, the pathogenetic treatment of anemia with drugs that stimulate erythropoiesis, started during the period of antitumor therapy, has the greatest effect on the favorable outcome, which causes an increase in frequency of favorable outcomes to 5.5 and 4.8 % over 3 and 5 years, respectively.Conclusion. The methodological approach developed by us to assess probabilities of formation of adverse outcomes in patients with anemia in malignant neoplasms can be used to solve expert and clinical problems, determination the risk of an unfavorable outcome and justification the indications for the timely start of therapy.
- Open Access
- 5 October 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (3) , 280-295
Primary cutaneous B-cell lymphomas: clinical and molecular analysis of the Russian Group for the Study of Cutaneous Lymphomas
Introduction. Primary cutaneous B-cell lymphomas (PCBCL) are a rare group of lymphoproliferative diseases with diverse clinical manifestations, differential diagnostic algorithms, treatment options, and prognoses. Aim : to characterize patients with PCBCL according to clinical, pathomorphological and cytogenetic parameters. Materials and methods . Data from 57 patients with PCBCL, who had been observed and/or treated between January 2011 and December 2023, were retrospectively analyzed and included in the study conducted by the Russian Group for the Study of Cutaneous Lymphomas. Results. The most common subtype was primary cutaneous diffuse large B-cell lymphoma (PC-DLBCL) (40 %), while primary cutaneous marginal zone lymphoma (PC-MZL) and primary cutaneous follicle center lymphoma (PC-FCL) accounted for 32 % and 28 %, respectively. The long-term overall survival rate of PCBCL was 90 % in the entire group and indicates a favorable prognosis for PCBCL. At the time of diagnosis verifi cation, 42 out of 55 patients had indications for therapy (33 % in indolent cases, 100 % in PCDLBCL). Of these, 89 % had a complete response after the fi rst line (PCFCL — 93 %, PCMZL — 94 %, PCDLBCL — 78 %). For patients with PCDLBCL, effi cacy was demonstrated when using systemic chemotherapy according to the mNHL BFM-90 protocol: 5-year disease-free survival (DFS) and event-free survival (EFS) were 83 % and 76 %, respectively. For PCFCL and PCMZL, effi cacy was demonstrated with surgical resection and radiation therapy (5-year DFS and EFS were 71 % and 67 %, respectively). The analysis of the identifi cation of factors of the unfavorable course of the disease revealed an increase in the risk of recurrence/ progression by 40 % with lower limb damage in all PCBCL variants. Conclusion. For PCFCL and PCMZL, radiation therapy demonstrated the highest therapeutic effi cacy. In patients with PCDLBCL, various chemotherapy regimens are indicated at the stage of diagnosis verifi cation, with high-dose chemotherapy being the most effective. Localization of the pathological process in the lower limbs is associated with an increased risk of relapse across all PCBCL subtypes.
- 5 October 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (3) , 280-295
Open AccessPrimary cutaneous B-cell lymphomas: clinical and molecular analysis of the Russian Group for the Study of Cutaneous Lymphomas
Introduction. Primary cutaneous B-cell lymphomas (PCBCL) are a rare group of lymphoproliferative diseases with diverse clinical manifestations, differential diagnostic algorithms, treatment options, and prognoses. Aim : to characterize patients with PCBCL according to clinical, pathomorphological and cytogenetic parameters. Materials and methods . Data from 57 patients with PCBCL, who had been observed and/or treated between January 2011 and December 2023, were retrospectively analyzed and included in the study conducted by the Russian Group for the Study of Cutaneous Lymphomas. Results. The most common subtype was primary cutaneous diffuse large B-cell lymphoma (PC-DLBCL) (40 %), while primary cutaneous marginal zone lymphoma (PC-MZL) and primary cutaneous follicle center lymphoma (PC-FCL) accounted for 32 % and 28 %, respectively. The long-term overall survival rate of PCBCL was 90 % in the entire group and indicates a favorable prognosis for PCBCL. At the time of diagnosis verifi cation, 42 out of 55 patients had indications for therapy (33 % in indolent cases, 100 % in PCDLBCL). Of these, 89 % had a complete response after the fi rst line (PCFCL — 93 %, PCMZL — 94 %, PCDLBCL — 78 %). For patients with PCDLBCL, effi cacy was demonstrated when using systemic chemotherapy according to the mNHL BFM-90 protocol: 5-year disease-free survival (DFS) and event-free survival (EFS) were 83 % and 76 %, respectively. For PCFCL and PCMZL, effi cacy was demonstrated with surgical resection and radiation therapy (5-year DFS and EFS were 71 % and 67 %, respectively). The analysis of the identifi cation of factors of the unfavorable course of the disease revealed an increase in the risk of recurrence/ progression by 40 % with lower limb damage in all PCBCL variants. Conclusion. For PCFCL and PCMZL, radiation therapy demonstrated the highest therapeutic effi cacy. In patients with PCDLBCL, various chemotherapy regimens are indicated at the stage of diagnosis verifi cation, with high-dose chemotherapy being the most effective. Localization of the pathological process in the lower limbs is associated with an increased risk of relapse across all PCBCL subtypes.
- Open Access
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 27-39
TP53 gene mutations and cytogenetic aberrations in tumor cells of patients with primary mediastinal B-cell large cell lymphoma
Introduction. TP53 gene mutations and cytogenetic abnormalities (MYC/8q24, BCL2/18q21, BCL6/3q27, del17p13, and complex karyotype) play an important role in prognosis and therapy selection for various lymphoproliferative diseases. However, their signifi cance in the pathogenesis and prognosis of primary mediastinal B-cell large cell lymphoma (PMBCL) remains poorly understood and warrants further investigation.Aim: to assess the frequency of TP53 gene mutations and cytogenetic aberrations (MYC/8q24, BCL2/18q21, BCL6/3q27, del17p13, and complex karyotype) and their impact on treatment outcomes in PMBCL.Materials and methods. The study included 51 patients who underwent therapy using the response-adapted DA-EPOCHR protocol from 2012 to 2024. Analysis of TP53 mutations (exons 4–10) was performed using high-throughput sequencing (n = 31/51 (61 %)). FISH analysis was conducted to identify chromosomal abnormalities involving the loci of MYC/8q24, BCL2/18q21, BCL6/3q27, and del17p13 (n = 31/51 (61 %)), and standard karyotyping was carried out (n = 31/51 (61 %)). Due to the low mitotic activity of tumor cells, suffi cient mitoses were obtained in only 16/31 (52%) PMBCL samples.Results. TP53 mutations were identifi ed in 4/31 (13%) patients, with three of these mutations classifi ed as pathogenic. Isolated translocations involving MYC/8q24 and BCL6/3q27 loci were detected in 2/31 (6 %) patients. Structural rearrangements of chromosome 17 in the TP53 locus and translocations involving the BCL2/18q21 locus were not identifi ed in any case. At 36 months, overall survival in the TP53-WT and TP53-MUT groups was 85 % and 100 %, respectively (p = 0.61). The relapse/progression rate was 33 % in TP53-MUT patients and 20 % in TP53-WT patients (p = 0.35).Conclusion. The fi ndings demonstrate the rarity and lack of prognostic signifi cance of the investigated markers in PMBCL patients. These results underscore the need for further research to identify driver events in biologically discrete subtypes of aggressive B-cell lymphomas, as well as risk factors specifi c to each subtype. Such research will provide a foundation for the development of precision therapy approaches.
- 13 March 2025
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 70 (1) , 27-39
Open AccessTP53 gene mutations and cytogenetic aberrations in tumor cells of patients with primary mediastinal B-cell large cell lymphoma
Introduction. TP53 gene mutations and cytogenetic abnormalities (MYC/8q24, BCL2/18q21, BCL6/3q27, del17p13, and complex karyotype) play an important role in prognosis and therapy selection for various lymphoproliferative diseases. However, their signifi cance in the pathogenesis and prognosis of primary mediastinal B-cell large cell lymphoma (PMBCL) remains poorly understood and warrants further investigation.Aim: to assess the frequency of TP53 gene mutations and cytogenetic aberrations (MYC/8q24, BCL2/18q21, BCL6/3q27, del17p13, and complex karyotype) and their impact on treatment outcomes in PMBCL.Materials and methods. The study included 51 patients who underwent therapy using the response-adapted DA-EPOCHR protocol from 2012 to 2024. Analysis of TP53 mutations (exons 4–10) was performed using high-throughput sequencing (n = 31/51 (61 %)). FISH analysis was conducted to identify chromosomal abnormalities involving the loci of MYC/8q24, BCL2/18q21, BCL6/3q27, and del17p13 (n = 31/51 (61 %)), and standard karyotyping was carried out (n = 31/51 (61 %)). Due to the low mitotic activity of tumor cells, suffi cient mitoses were obtained in only 16/31 (52%) PMBCL samples.Results. TP53 mutations were identifi ed in 4/31 (13%) patients, with three of these mutations classifi ed as pathogenic. Isolated translocations involving MYC/8q24 and BCL6/3q27 loci were detected in 2/31 (6 %) patients. Structural rearrangements of chromosome 17 in the TP53 locus and translocations involving the BCL2/18q21 locus were not identifi ed in any case. At 36 months, overall survival in the TP53-WT and TP53-MUT groups was 85 % and 100 %, respectively (p = 0.61). The relapse/progression rate was 33 % in TP53-MUT patients and 20 % in TP53-WT patients (p = 0.35).Conclusion. The fi ndings demonstrate the rarity and lack of prognostic signifi cance of the investigated markers in PMBCL patients. These results underscore the need for further research to identify driver events in biologically discrete subtypes of aggressive B-cell lymphomas, as well as risk factors specifi c to each subtype. Such research will provide a foundation for the development of precision therapy approaches.
- Open Access
- 29 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10482
Biallelic Loss of 7q34 (TRB) and 9p21.3 (CDKN2A/2B) in Adult Ph-Negative Acute T-Lymphoblastic Leukemia
Tumor cells of acute lymphoblastic leukemia (ALL) may have various genetic abnormalities. Some of them lead to a complete loss of certain genes. Our aim was to reveal biallelic deletions of genes in Ph–negative T-ALL. Chromosomal microarray analysis (CMA) was performed for 47 patients with de novo Ph–negative T-ALL, who received treatment according to RALL-2016m clinical protocol at the National Medical Research Center for Hematology (Moscow, Russia) from 2017 to 2023. Out of forty-seven patients, only three had normal molecular karyotype. The other 44 patients had multiple gains, losses, and copy neutral losses of heterozygosity. Biallelic losses were found in 14 patients (30%). In ten patients (21%), a biallelic deletion of 9p21.3 involved a different number of genes, however CDKN2A gene loss was noted in all ten cases. For seven patients (15%), a biallelic deletion of 7q34 was found, including two genes—PRSS1, PRSS2 located within the T-cell receptor beta (TRB) locus. A clonal rearrangement of the TRB gene was revealed in 6 out of 7 cases with 7q34 biallelic loss. Both biallelic deletions can be considered favorable prognostic factors, with an association with 9p21 being statistically significant (p = 0.01) and a trend for 7q34 (p = 0.12) being observed.
- 29 September 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (19) , 10482
Open AccessBiallelic Loss of 7q34 (TRB) and 9p21.3 (CDKN2A/2B) in Adult Ph-Negative Acute T-Lymphoblastic Leukemia
Tumor cells of acute lymphoblastic leukemia (ALL) may have various genetic abnormalities. Some of them lead to a complete loss of certain genes. Our aim was to reveal biallelic deletions of genes in Ph–negative T-ALL. Chromosomal microarray analysis (CMA) was performed for 47 patients with de novo Ph–negative T-ALL, who received treatment according to RALL-2016m clinical protocol at the National Medical Research Center for Hematology (Moscow, Russia) from 2017 to 2023. Out of forty-seven patients, only three had normal molecular karyotype. The other 44 patients had multiple gains, losses, and copy neutral losses of heterozygosity. Biallelic losses were found in 14 patients (30%). In ten patients (21%), a biallelic deletion of 9p21.3 involved a different number of genes, however CDKN2A gene loss was noted in all ten cases. For seven patients (15%), a biallelic deletion of 7q34 was found, including two genes—PRSS1, PRSS2 located within the T-cell receptor beta (TRB) locus. A clonal rearrangement of the TRB gene was revealed in 6 out of 7 cases with 7q34 biallelic loss. Both biallelic deletions can be considered favorable prognostic factors, with an association with 9p21 being statistically significant (p = 0.01) and a trend for 7q34 (p = 0.12) being observed.
- Open Access
- 29 January 2024
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (2) , 3784
Diagnostic capabilities of instrumental methods for studying early cardiovascular adverse events in patients with lymphoproliferative disorders, quality and safety issues
Aim. To study the possibilities of instrumental research methods in relation to the earliest detection of cardiovascular events in oncohematological patients receiving antitumor immunochemotherapy, as well as to determine the requirements for documenting adverse events.Material and methods. For the study, 63 patients were prospectively selected with a diagnosis of indolent non-Hodgkin lymphoma, who were indicated for antitumor immunochemotherapy. The patients were examined in three stages (before treatment, after 3 and 6 cycles of therapy) and divided into 2 groups by simple randomization. Cardiovascular toxicity in the main group of patients was assessed using 3D transthoracic echocardiography, analysis of left ventricular (LV) global longitudinal systolic strain and electrocardiography. The control group underwent a standard 3D echocardiography with analysis of LV ejection fraction. Clinical manifestations of cardiovascular events were assessed in all patients during treatment.Results. According to the study, significant changes were obtained in LV ejection fraction on the third visit — a decrease from 58,9±1,07 to 48,1±0,73% (pConclusion. The long period of latent cardiovascular toxicity emphasizes the need for early verification of cardiovascular complications of antitumor therapy and expansion of the established paraclinical diagnostic minimum. In addition, taking into account the accumulated experience, recommendations are presented for the preparation of medical documentation in order to ensure the safety and quality of care.
- 29 January 2024
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (2) , 3784
Open AccessDiagnostic capabilities of instrumental methods for studying early cardiovascular adverse events in patients with lymphoproliferative disorders, quality and safety issues
Aim. To study the possibilities of instrumental research methods in relation to the earliest detection of cardiovascular events in oncohematological patients receiving antitumor immunochemotherapy, as well as to determine the requirements for documenting adverse events.Material and methods. For the study, 63 patients were prospectively selected with a diagnosis of indolent non-Hodgkin lymphoma, who were indicated for antitumor immunochemotherapy. The patients were examined in three stages (before treatment, after 3 and 6 cycles of therapy) and divided into 2 groups by simple randomization. Cardiovascular toxicity in the main group of patients was assessed using 3D transthoracic echocardiography, analysis of left ventricular (LV) global longitudinal systolic strain and electrocardiography. The control group underwent a standard 3D echocardiography with analysis of LV ejection fraction. Clinical manifestations of cardiovascular events were assessed in all patients during treatment.Results. According to the study, significant changes were obtained in LV ejection fraction on the third visit — a decrease from 58,9±1,07 to 48,1±0,73% (pConclusion. The long period of latent cardiovascular toxicity emphasizes the need for early verification of cardiovascular complications of antitumor therapy and expansion of the established paraclinical diagnostic minimum. In addition, taking into account the accumulated experience, recommendations are presented for the preparation of medical documentation in order to ensure the safety and quality of care.
- Open Access
- 28 December 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (4) , 456-471
Staffing of the hematology service of the Russian Federation
Introduction. As part of the implementation of the federal project Development of a network of national medical research centers and the introduction of innovative medical technologies, one of the activities of the National Medical Research Center for Hematology (Center) is the analysis of the staffi ng of medical organizations (MO) of the constituent entities of the Russian Federation (RF) by hematologists.Aim — to analyze the dynamics of staffi ng by hematologists of MO in the RF.Materials and methods. Data from the Federal State Statistics Service (Rosstat) — Federal Statistical Observation Form No. 30 “Information about a medical organization” of the constituent entities of the Russian Federation for 2012–2020, reference books of the Central Research Institute of Organization and Informatization Health of the Russian Ministry of Health in the Russian Federation, information obtained from the results of on-site events of the National Medical Research Center for Hematology, including expert assessments were used.Results. The hematological service is organized in all subjects of the RF, with the exception of the Chukotka and Nenets Autonomous Okrug, Republic of Kalmykia and Altai, as well as the Jewish Autonomous Region. As of December 31, 2021, 1,594 hematologists work in the constituent entities of the RF, of which 460 specialists are in outpatient care and 1133 specialists in hospital settings. Analysis of the availability of full-time positions of hematologists per 10,000 populations in the Russian Federation in dynamics for 2012–2020 revealed fl uctuations in the values of this indicator from 0.06 to 0.17. The largest “failure” in the provision of hematologists occurred in 2014 in almost all federal districts (FD) of the Russian Federation. Only the Urals FD maintains the stability of the indicator of availability of these specialists. Over the past 3 years, there has been an increase in the number of full-time positions of hematologists, while the staffi ng of individuals reduced due to the lack (increase) of new employees and slightly offset by an increase in the coeffi cient of internal part-time work. Thus, the highest combination coeffi cient was noted in 2020 in the Ural (1.49) and Siberian (1.45) FD, the lowest in the North-Western FD (1.09). In accordance with the legal act regulating the activities of the hematology service, the standard for calculating the positions of outpatient hematologists is 1 doctor per 200 thousand of the population, however, the provision of full-time positions for the outpatient stage of care remains not achieved (2021 — 0.92 per 200 thousand); at least 731 doctors are needed against the existing 456 specialists. The staffi ng standard of the department of hematology corresponds to one medical position per 10 beds. Compliance with regulations regarding the formation of the staffi ng table of the inpatient unit was noted in 95% of the constituent entities of the Russian Federation.Conclusion. The issues of personnel shortage of hematologists are relevant. The shortage of hematologists in the Russian Federation indicates the lack of attractiveness of remuneration and indicates the need for management decisions to be made by the Government of the Russian Federation and executive authorities of the constituent entities of the Russian Federation aimed at developing mechanisms for maintaining the human resource of hematologists in the healthcare system.
- 28 December 2023
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 68 (4) , 456-471
Open AccessStaffing of the hematology service of the Russian Federation
Introduction. As part of the implementation of the federal project Development of a network of national medical research centers and the introduction of innovative medical technologies, one of the activities of the National Medical Research Center for Hematology (Center) is the analysis of the staffi ng of medical organizations (MO) of the constituent entities of the Russian Federation (RF) by hematologists.Aim — to analyze the dynamics of staffi ng by hematologists of MO in the RF.Materials and methods. Data from the Federal State Statistics Service (Rosstat) — Federal Statistical Observation Form No. 30 “Information about a medical organization” of the constituent entities of the Russian Federation for 2012–2020, reference books of the Central Research Institute of Organization and Informatization Health of the Russian Ministry of Health in the Russian Federation, information obtained from the results of on-site events of the National Medical Research Center for Hematology, including expert assessments were used.Results. The hematological service is organized in all subjects of the RF, with the exception of the Chukotka and Nenets Autonomous Okrug, Republic of Kalmykia and Altai, as well as the Jewish Autonomous Region. As of December 31, 2021, 1,594 hematologists work in the constituent entities of the RF, of which 460 specialists are in outpatient care and 1133 specialists in hospital settings. Analysis of the availability of full-time positions of hematologists per 10,000 populations in the Russian Federation in dynamics for 2012–2020 revealed fl uctuations in the values of this indicator from 0.06 to 0.17. The largest “failure” in the provision of hematologists occurred in 2014 in almost all federal districts (FD) of the Russian Federation. Only the Urals FD maintains the stability of the indicator of availability of these specialists. Over the past 3 years, there has been an increase in the number of full-time positions of hematologists, while the staffi ng of individuals reduced due to the lack (increase) of new employees and slightly offset by an increase in the coeffi cient of internal part-time work. Thus, the highest combination coeffi cient was noted in 2020 in the Ural (1.49) and Siberian (1.45) FD, the lowest in the North-Western FD (1.09). In accordance with the legal act regulating the activities of the hematology service, the standard for calculating the positions of outpatient hematologists is 1 doctor per 200 thousand of the population, however, the provision of full-time positions for the outpatient stage of care remains not achieved (2021 — 0.92 per 200 thousand); at least 731 doctors are needed against the existing 456 specialists. The staffi ng standard of the department of hematology corresponds to one medical position per 10 beds. Compliance with regulations regarding the formation of the staffi ng table of the inpatient unit was noted in 95% of the constituent entities of the Russian Federation.Conclusion. The issues of personnel shortage of hematologists are relevant. The shortage of hematologists in the Russian Federation indicates the lack of attractiveness of remuneration and indicates the need for management decisions to be made by the Government of the Russian Federation and executive authorities of the constituent entities of the Russian Federation aimed at developing mechanisms for maintaining the human resource of hematologists in the healthcare system.